<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00047385</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02002</org_study_id>
    <secondary_id>U01CA079778</secondary_id>
    <secondary_id>U01CA080098</secondary_id>
    <secondary_id>N1CN25476A-85-0-1</secondary_id>
    <secondary_id>NIH/NCI</secondary_id>
    <secondary_id>CDR0000257938</secondary_id>
    <nct_id>NCT00047385</nct_id>
    <nct_alias>NCT00028808</nct_alias>
  </id_info>
  <brief_title>National Lung Screening Trial (NLST) Screening</brief_title>
  <acronym>NLST</acronym>
  <official_title>National Lung Screening Trial A Randomized Trial Comparing Low-dose Helical CT With Chest Xray for Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Radiology Imaging Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Effective screening tests should help doctors detect lung cancer early and plan
      curative treatment. It is not yet known whether low-dose helical computed tomography (LDCT)
      screening is more effective than chest radiography (CXR) screening in reducing death from
      lung cancer.

      PURPOSE: Randomized clinical trial to compare the effectiveness of LDCT scan with that of CXR
      in screening individuals who are at high risk for developing lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare whether screening with low-dose helical CT scan vs chest x-ray reduces lung
           cancer-specific mortality in participants who are at high risk for developing lung
           cancer.

      OUTLINE:

      NLST participants were randomized to either low-dose helical CT or chest x-ray in equal
      proportions. A total of 53,454 participants were enrolled (26,722 in low-dose CT and 26,732
      in chest radiography) at 33 screening centers across the United States. Screening was offered
      three times (at baseline and two annual follow-up examinations). The primary endpoint of the
      study was lung cancer mortality. The study arms were compared with regard to overall
      mortality, lung cancer incidence, and screening-related complications.

      All low-dose scanners and chest x-ray machines were certified for use and met NLST protocol
      requirements and American College of Radiology guidelines. Low-dose CT acquisitions and chest
      radiographs were interpreted by trained radiologists. Participants and their health care
      provider were informed of study examination results. Participants with abnormalities
      suspicious for lung cancer were contacted for information regarding diagnostic evaluation.
      Medical records were collected on diagnostic evaluation, medical complications, and initial
      treatment.

      Participants were then contacted at least annually by mail or telephone.

      The National Lung Screening Trial (NLST) represents the union of two NCI-sponsored efforts,
      the NCI Lung Screening Study and the American College of Radiology Imaging Network (ACRIN).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung Cancer Deaths</measure>
    <time_frame>All events through December 31, 2009; median follow-up 6.5 years.</time_frame>
    <description>Lung cancer deaths confirmed in participants by Endpoint Verification if available, otherwise by death certificate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deaths From All Causes in All Randomized Participants.</measure>
    <time_frame>All events through December 31, 2009; median follow-up 6.5 years.</time_frame>
    <description>Deaths from all causes were compared between the low-dose CT group and the chest radiography group among all randomized participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Cancer Diagnoses</measure>
    <time_frame>All events through December 31, 2009; median follow-up 6.5 years</time_frame>
    <description>Lung cancer diagnoses confirmed by medical record abstraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of Diagnostic Evaluation Following a Positive Screening Test.</measure>
    <time_frame>One year from screening examination</time_frame>
    <description>Number of participants who experienced complications during diagnostic work-up of a screening CT or CXR that was suspicious for lung cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T0 (Baseline) Screening Results</measure>
    <time_frame>T0 (at study entry)</time_frame>
    <description>Results of radiologist's interpretation of images from LDCT or CXR screening exam at T0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1 Screening Results</measure>
    <time_frame>T1 (one year after entry)</time_frame>
    <description>Results of radiologist's interpretation of images from LDCT or CXR screening exam at T1. Includes a comparison with images from T0 screen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T2 Screening Results</measure>
    <time_frame>T2 (two years after entry)</time_frame>
    <description>Results of radiologist's interpretation of images from LDCT or CXR screening exam at T2. Includes a comparison with images from T0 and T1 screens.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53454</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Low-Dose CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chest X-ray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>low-dose helical computed tomography</intervention_name>
    <description>A LDCT is a computerized tomography image with low-dose technique without contrast. The scan is done from the neck to the diaphragm in one breath-hold.</description>
    <arm_group_label>Low-Dose CT</arm_group_label>
    <other_name>LDCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>chest radiography</intervention_name>
    <description>The chest x-ray in this study was a single posterior-anterior film done with the participant upright.</description>
    <arm_group_label>Chest X-ray</arm_group_label>
    <other_name>CXR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 55-74 years (pack-years = packs per day * years smoked)

          -  30 or more pack-years of cigarette smoking history

          -  Former smokers: quit smoking within the previous 15 years

          -  Ability to lie on the back with arms raised over the head

          -  Signed informed consent form

        Exclusion Criteria:

          -  Metallic implants or devices in the chest or back, such as pacemakers or Harrington
             fixation rods

          -  Treatment for, or evidence of, any cancer other than nonmelanoma skin cancer or
             carcinoma in situ (with the exception of transitional cell carcinoma in situ or
             bladder carcinoma in situ) in the 5 years prior to eligibility assessment

          -  History of lung cancer

          -  History of removal of any portion of the lung, excluding needle biopsy

          -  Requirement for home oxygen supplementation

          -  Participation in another cancer screening trial

          -  Participation in a cancer prevention study, other than a smoking cessation study

          -  Unexplained weight loss of more than 15 pounds in the 12 months prior to eligibility
             assessment

          -  Recent hemoptysis

          -  Pneumonia or acute respiratory infection treated with antibiotics in the 12 weeks
             prior to eligibility assessment

          -  Chest CT examination in the 18 months prior to eligibility assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine D. Berg, MD</last_name>
    <role>Study Director</role>
    <affiliation>NCI - Early Detection Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denise R. Aberle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Health Research &amp; Education Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hopsital Heart and Lung Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Foundation Hospital</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota School of Public Health</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Elizabeth Health Center</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University, Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908-4735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic Research Foundation</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cancer.gov/nlst</url>
    <description>Web site for additional information</description>
  </link>
  <reference>
    <citation>National Lung Screening Trial Research Team, Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall M, Sullivan DC, Sullivan D, Zylak CJ. The National Lung Screening Trial: overview and study design. Radiology. 2011 Jan;258(1):243-53. doi: 10.1148/radiol.10091808. Epub 2010 Nov 2.</citation>
    <PMID>21045183</PMID>
  </reference>
  <reference>
    <citation>Cody DD, Kim HJ, Cagnon CH, Larke FJ, McNitt-Gray MM, Kruger RL, Flynn MJ, Seibert JA, Judy PF, Wu X. Normalized CT dose index of the CT scanners used in the National Lung Screening Trial. AJR Am J Roentgenol. 2010 Jun;194(6):1539-46. doi: 10.2214/AJR.09.3268.</citation>
    <PMID>20489094</PMID>
  </reference>
  <reference>
    <citation>Clark KW, Gierada DS, Marquez G, Moore SM, Maffitt DR, Moulton JD, Wolfsberger MA, Koppel P, Phillips SR, Prior FW. Collecting 48,000 CT exams for the lung screening study of the National Lung Screening Trial. J Digit Imaging. 2009 Dec;22(6):667-80. doi: 10.1007/s10278-008-9145-9. Epub 2008 Sep 6.</citation>
    <PMID>18777192</PMID>
  </reference>
  <reference>
    <citation>Gierada DS, Garg K, Nath H, Strollo DC, Fagerstrom RM, Ford MB. CT quality assurance in the lung screening study component of the National Lung Screening Trial: implications for multicenter imaging trials. AJR Am J Roentgenol. 2009 Aug;193(2):419-24. doi: 10.2214/AJR.08.1995.</citation>
    <PMID>19620438</PMID>
  </reference>
  <results_reference>
    <citation>National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.</citation>
    <PMID>21714641</PMID>
  </results_reference>
  <results_reference>
    <citation>Singh S, Pinsky P, Fineberg NS, Gierada DS, Garg K, Sun Y, Nath PH. Evaluation of reader variability in the interpretation of follow-up CT scans at lung cancer screening. Radiology. 2011 Apr;259(1):263-70. doi: 10.1148/radiol.10101254. Epub 2011 Jan 19.</citation>
    <PMID>21248232</PMID>
  </results_reference>
  <results_reference>
    <citation>National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, Gareen IF, Lynch DA, Marcus PM, Pinsky PF. Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst. 2010 Dec 1;102(23):1771-9. doi: 10.1093/jnci/djq434. Epub 2010 Nov 22. Erratum in: J Natl Cancer Inst. 2011 Oct 19;103(20):1560.</citation>
    <PMID>21119104</PMID>
  </results_reference>
  <results_reference>
    <citation>Park ER, Ostroff JS, Rakowski W, Gareen IF, Diefenbach MA, Feibelmann S, Rigotti NA. Risk perceptions among participants undergoing lung cancer screening: baseline results from the National Lung Screening Trial. Ann Behav Med. 2009 Jun;37(3):268-79. doi: 10.1007/s12160-009-9112-9. Epub 2009 Aug 27.</citation>
    <PMID>19711141</PMID>
  </results_reference>
  <results_reference>
    <citation>Gierada DS, Pilgram TK, Ford M, Fagerstrom RM, Church TR, Nath H, Garg K, Strollo DC. Lung cancer: interobserver agreement on interpretation of pulmonary findings at low-dose CT screening. Radiology. 2008 Jan;246(1):265-72. Epub 2007 Nov 16.</citation>
    <PMID>18024436</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>May 30, 2012</results_first_submitted>
  <results_first_submitted_qc>May 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 6, 2012</results_first_posted>
  <last_update_submitted>May 2, 2014</last_update_submitted>
  <last_update_submitted_qc>May 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>small cell lung cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was from August 2002 through April 2004 at 33 NLST sites.</recruitment_details>
      <pre_assignment_details>Participants signed a study informed consent prior to being randomized to a study arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low-Dose CT</title>
          <description>Participants undergo low-dose helical CT examination.</description>
        </group>
        <group group_id="P2">
          <title>Chest X-ray</title>
          <description>Participants undergo chest x-ray examination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26722"/>
                <participants group_id="P2" count="26732"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26455">Had at least one screening exam.</participants>
                <participants group_id="P2" count="26232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="500"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death before any screening</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lung Cancer diagnosed before screening</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligible for screening but had no screen</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="492"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low-Dose CT</title>
          <description>Participants undergo low-dose helical CT examination.</description>
        </group>
        <group group_id="B2">
          <title>Chest X-ray</title>
          <description>Participants undergo chest x-ray examination.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26722"/>
            <count group_id="B2" value="26732"/>
            <count group_id="B3" value="53454"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19612"/>
                    <measurement group_id="B2" value="19622"/>
                    <measurement group_id="B3" value="39234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7110"/>
                    <measurement group_id="B2" value="7110"/>
                    <measurement group_id="B3" value="14220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="5.0"/>
                    <measurement group_id="B2" value="61.4" spread="5.0"/>
                    <measurement group_id="B3" value="61.4" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10952"/>
                    <measurement group_id="B2" value="10970"/>
                    <measurement group_id="B3" value="21922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15770"/>
                    <measurement group_id="B2" value="15762"/>
                    <measurement group_id="B3" value="31532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26,722"/>
                    <measurement group_id="B2" value="26,732"/>
                    <measurement group_id="B3" value="53454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lung Cancer Deaths</title>
        <description>Lung cancer deaths confirmed in participants by Endpoint Verification if available, otherwise by death certificate.</description>
        <time_frame>All events through December 31, 2009; median follow-up 6.5 years.</time_frame>
        <population>All participants randomized were analyzed. An intention-to-treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>LDCT Screening</title>
            <description>Participants randomized to receive three annual low-dose helical CT exams of the chest.</description>
          </group>
          <group group_id="O2">
            <title>CXR Screening</title>
            <description>Participants randomized to receive three annual chest radiographs.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Cancer Deaths</title>
          <description>Lung cancer deaths confirmed in participants by Endpoint Verification if available, otherwise by death certificate.</description>
          <population>All participants randomized were analyzed. An intention-to-treat analysis was performed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26722"/>
                <count group_id="O2" value="26732"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356"/>
                    <measurement group_id="O2" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis: LDCT screening reduces lung cancer mortality relative to chest x-ray.
Power: 90% for a 20% reduction in lung cancer mortality.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is adjusted for multiple comparisons.</p_value_desc>
            <method>Weighted log-rank (details below)</method>
            <method_desc>Weights in weighted log-rank statistic increased linearly from zero at randomization to full weight at 4 years and thereafter.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.800</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.733</ci_lower_limit>
            <ci_upper_limit>0.932</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deaths From All Causes in All Randomized Participants.</title>
        <description>Deaths from all causes were compared between the low-dose CT group and the chest radiography group among all randomized participants.</description>
        <time_frame>All events through December 31, 2009; median follow-up 6.5 years.</time_frame>
        <population>All participants randomized were analyzed. An intention-to-treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>LDCT Screening</title>
            <description>Participants randomized to receive three annual low-dose helical CT exams of the chest.</description>
          </group>
          <group group_id="O2">
            <title>CXR Screening</title>
            <description>Participants randomized to receive three annual chest radiographs.</description>
          </group>
        </group_list>
        <measure>
          <title>Deaths From All Causes in All Randomized Participants.</title>
          <description>Deaths from all causes were compared between the low-dose CT group and the chest radiography group among all randomized participants.</description>
          <population>All participants randomized were analyzed. An intention-to-treat analysis was performed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26722"/>
                <count group_id="O2" value="26732"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1877"/>
                    <measurement group_id="O2" value="2000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis: LDCT screening reduced all-cause mortality relative to chest x-ray.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>No adjustment for multiple comparisons. Only one analysis performed.</p_value_desc>
            <method>Weighted log-rank (details below)</method>
            <method_desc>Weights in weighted log-rank statistic increased linearly from zero at randomization to full weight at 4 years and thereafter.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.933</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.864</ci_lower_limit>
            <ci_upper_limit>0.988</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Cancer Diagnoses</title>
        <description>Lung cancer diagnoses confirmed by medical record abstraction.</description>
        <time_frame>All events through December 31, 2009; median follow-up 6.5 years</time_frame>
        <population>All participants randomized were analyzed. An intention-to-treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>LDCT Screening</title>
            <description>Participants randomized to receive three annual low-dose helical CT exams of the chest.</description>
          </group>
          <group group_id="O2">
            <title>CXR Screening</title>
            <description>Participants randomized to receive three annual chest radiographs.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Cancer Diagnoses</title>
          <description>Lung cancer diagnoses confirmed by medical record abstraction.</description>
          <population>All participants randomized were analyzed. An intention-to-treat analysis was performed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26722"/>
                <count group_id="O2" value="26732"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1060"/>
                    <measurement group_id="O2" value="941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Denominator: LDCT Group Numerator: CXR Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications of Diagnostic Evaluation Following a Positive Screening Test.</title>
        <description>Number of participants who experienced complications during diagnostic work-up of a screening CT or CXR that was suspicious for lung cancer.</description>
        <time_frame>One year from screening examination</time_frame>
        <population>The units analyzed were positive screening exams with documented diagnostic follow-up. If participant received 3 positive screens with documented follow-up after each one, he/she would be counted 3 times in the number of units analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LDCT Screening</title>
            <description>Participants randomized to receive three annual low-dose helical CT exams of the chest.</description>
          </group>
          <group group_id="O2">
            <title>CXR Screening</title>
            <description>Participants randomized to receive three annual chest radiographs.</description>
          </group>
        </group_list>
        <measure>
          <title>Complications of Diagnostic Evaluation Following a Positive Screening Test.</title>
          <description>Number of participants who experienced complications during diagnostic work-up of a screening CT or CXR that was suspicious for lung cancer.</description>
          <population>The units analyzed were positive screening exams with documented diagnostic follow-up. If participant received 3 positive screens with documented follow-up after each one, he/she would be counted 3 times in the number of units analyzed.</population>
          <units>Pos. screens w/ complications</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26722"/>
                <count group_id="O2" value="26732"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Positive Screens with Follow-up</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17702"/>
                <count group_id="O2" value="4953"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T0 (Baseline) Screening Results</title>
        <description>Results of radiologist's interpretation of images from LDCT or CXR screening exam at T0.</description>
        <time_frame>T0 (at study entry)</time_frame>
        <population>All participants randomized were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LDCT Screening</title>
            <description>Participants randomized to receive three annual low-dose helical CT exams of the chest.</description>
          </group>
          <group group_id="O2">
            <title>CXR Screening</title>
            <description>Participants randomized to receive three annual chest radiographs.</description>
          </group>
        </group_list>
        <measure>
          <title>T0 (Baseline) Screening Results</title>
          <description>Results of radiologist's interpretation of images from LDCT or CXR screening exam at T0.</description>
          <population>All participants randomized were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26722"/>
                <count group_id="O2" value="26732"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7191"/>
                    <measurement group_id="O2" value="2387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant abnor. not suspicious for lung cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2695"/>
                    <measurement group_id="O2" value="785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No, or minor abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16423"/>
                    <measurement group_id="O2" value="22863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eligible but not screened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406"/>
                    <measurement group_id="O2" value="689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not eligible for screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1 Screening Results</title>
        <description>Results of radiologist's interpretation of images from LDCT or CXR screening exam at T1. Includes a comparison with images from T0 screen.</description>
        <time_frame>T1 (one year after entry)</time_frame>
        <population>All participants randomized were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>LDCT Screening</title>
            <description>Participants randomized to receive three annual low-dose helical CT exams of the chest.</description>
          </group>
          <group group_id="O2">
            <title>CXR Screening</title>
            <description>Participants randomized to receive three annual chest radiographs.</description>
          </group>
        </group_list>
        <measure>
          <title>T1 Screening Results</title>
          <description>Results of radiologist's interpretation of images from LDCT or CXR screening exam at T1. Includes a comparison with images from T0 screen.</description>
          <population>All participants randomized were analyzed</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26722"/>
                <count group_id="O2" value="26732"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6901"/>
                    <measurement group_id="O2" value="1482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant abnor. not suspicious for lung cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1519"/>
                    <measurement group_id="O2" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No, or minor abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16295"/>
                    <measurement group_id="O2" value="22178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eligible but not screened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1570"/>
                    <measurement group_id="O2" value="2321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not eligible for screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437"/>
                    <measurement group_id="O2" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T2 Screening Results</title>
        <description>Results of radiologist's interpretation of images from LDCT or CXR screening exam at T2. Includes a comparison with images from T0 and T1 screens.</description>
        <time_frame>T2 (two years after entry)</time_frame>
        <population>All participants randomized were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>LDCT Screening</title>
            <description>Participants randomized to receive three annual low-dose helical CT exams of the chest.</description>
          </group>
          <group group_id="O2">
            <title>CXR Screening</title>
            <description>Participants randomized to receive three annual chest radiographs.</description>
          </group>
        </group_list>
        <measure>
          <title>T2 Screening Results</title>
          <description>Results of radiologist's interpretation of images from LDCT or CXR screening exam at T2. Includes a comparison with images from T0 and T1 screens.</description>
          <population>All participants randomized were analyzed</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26722"/>
                <count group_id="O2" value="26732"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4054"/>
                    <measurement group_id="O2" value="1174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant abnor. not suspicious for lung cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1408"/>
                    <measurement group_id="O2" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No, or minor abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18640"/>
                    <measurement group_id="O2" value="21811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eligible but not screened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1840"/>
                    <measurement group_id="O2" value="2764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not eligible for screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="780"/>
                    <measurement group_id="O2" value="622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During each annual screening visit.</time_frame>
      <desc>These events are solely those prompted by the screening examination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Low-Dose CT</title>
          <description>Participants undergo low-dose helical CT examination.</description>
        </group>
        <group group_id="E2">
          <title>Chest X-ray</title>
          <description>Participants undergo chest x-ray examination.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26722"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac symptoms</sub_title>
                <description>Shortness of breath, diaphoresis, jaw pain and general cardiac symptoms. Admitted to hospital; MI ruled out. Treated with medication/inhalers for COPD exacerbation. Stable through the admission; fully recovered the following day.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26722"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/vomiting, bradycardia, diaphoresis</sub_title>
                <description>Transient syncope w/ vomiting/bradycardia/diaphoresis/ashen color after phlebotomy and single forced expiration for spirometry.
Hospitalized for monitoring; MI ruled out. Recovered with time, rest, and liquids.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26722"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26732"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26722"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26732"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>NLST utilized institutions with special expertise. The &quot;healthy volunteer&quot; effect may apply. Scanners are now more technologically advanced. Ongoing LDCT screening may reduce the rate of lung cancer deaths more than three rounds done in NLST.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christine D. Berg, M.D.</name_or_title>
      <organization>Early Detection Research Group, NCI, NIH</organization>
      <phone>301-496-8544</phone>
      <email>bergc@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

